If you have been reading about GHRH analog and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-12-09. Where a claim depends on a specific study, the study is described rather than over-claimed.
Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized cake in single-use vials |
| Solubility class | Freely soluble in water | Reconstituted with sterile diluent before injection |
| Typical storage temperature | 2 to 8 degrees Celsius | Before reconstitution; protect from light |
| Typical analytical method | Reversed-phase high-performance liquid chromatography | Purity and related-substance testing |
| Identity confirmation | Mass spectrometry | Observed mass near 5.1 kDa for the intact peptide |
Storage claims vary across suppliers, and published stability data for specific formulations are limited. Extrapolating from related peptides is common but not a substitute for direct measurement. For research use, documentation such as a certificate of analysis is often requested to confirm identity and purity. What constitutes an acceptable purity threshold depends on the intended application. Open questions remain about how temperature excursions during shipping affect long-term peptide integrity. Independent verification by an end user is not routinely reported.
Lyophilized tesamorelin is generally stored refrigerated at 2 to 8 degrees Celsius, protected from light and moisture. Peptides in this class are often kept frozen at minus 20 degrees Celsius for longer periods. Reconstituted solutions are typically used within a defined window because hydrolysis and oxidation proceed faster in liquid form. Container material and headspace also influence how long a preparation retains its expected profile. Specific stability figures depend on concentration and buffer composition.
Common analytical approaches include reversed-phase high-performance liquid chromatography for purity assessment and mass spectrometry for identity confirmation. Peptide mapping after enzymatic digestion can verify the expected sequence. Immunoassays may be used to measure the compound or its downstream markers, but they can cross-react with related peptides and require careful validation. Impurity profiles typically include truncated sequences, oxidized methionine residues, and residual solvents from synthesis. Each method reports a different property, so no single assay establishes overall quality.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Published work tends to frame tesamorelin as a tool for studying the GHRH axis and as a compound with measurable effects on body composition. Reports often describe visceral adipose tissue as an endpoint, assessed by imaging rather than by inference. Analytical sections commonly describe liquid chromatography with tandem mass spectrometry to confirm identity and purity, because immunoassays may cross-react with related fragments. Where results diverge between studies, differences in assay choice, sampling timing, and population are frequent explanations offered. Whether effects persist after treatment stops remains an open question.
Tesamorelin binds the growth hormone–releasing hormone receptor on pituitary somatotroph cells. The receptor signals through the Gs protein, raising intracellular cAMP and activating protein kinase A. That cascade triggers release of stored growth hormone in pulses rather than a steady stream. Because the drug acts at the receptor that normally controls this process, its effect depends on the body's own signaling architecture rather than on a synthetic pathway. The resulting hormone profile reflects the timing of each pulse, not only its size.
监管记录显示，特沙莫瑞林于 2010 年在美国首次获得批准，用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验，而非体重或瘦体重的普遍改善。后续出现了不同制剂版本，但其核心适应症保持一致。关于长期心血管结局和死亡率影响，现有证据仍不充分。
在临床研究之外，特沙莫瑞林常被讨论为生长激素分泌促进剂，但这一说法需要限定。它并不等同于生长激素本身，也不属于普通减重药物。部分研究关注其减少腹部脂肪和改善脂质谱的潜力，另一些研究则关注胰岛素抵抗和 IGF-1 升高等信号。这些效应的临床意义仍在评估中，尚未形成统一结论。
The Platform 1 model is a "forward flight lift only" fixed-wing drone weighing 44 pounds (20 kg) and can carry up to 4 pounds (1.8 kg) of cargo. While they can fly 300 km (190 mi) on a charge, they limit themselves to destinations within 80 km (50 mi). The drones have a quickly-replaceable battery that allows rapid turnaround between flights. It has an inner carbon-fiber frame and an outer polystyrene shell. The wingspan is 11 feet (3.4 m). The drones have two propellers for redundancy and can fly safely on a single propeller or motor. A parachute that will bring the drone to the ground can be deployed if a larger set of faults occur. If the drone crashes, the outer components are frangible, breaking to release energy and impact the ground with less force. Zipline's drones are capable of "level 4" autonomy: the ability to complete travel autonomously under normal environmental conditions without requiring pilot oversight.
Faculty member Isabelle Rapin has been described as a "founding mother of autism" and popularized the term "autism spectrum disorder". In 2019, researchers at Einstein mapped the entire nervous system of Caenorhabditis elegans, a classic model organism. Other work includes the discovery of the Tc1/mariner transposon superfamily and the invention of single molecule mRNA fluorescent in situ hybridization.
=== Gas dissolving properties === Perfluorocarbons dissolve relatively high volumes of gases. The high solubility of gases is attributed to the weak intermolecular interactions in these fluorocarbon fluids. The table shows values for the mole fraction, x1, of nitrogen dissolved, calculated from the Blood–gas partition coefficient, at 298.15 K (25 °C), 0.101325 MPa.
=== Europe === Lancaster AMS-UK for trace actinides and radiocarbon at Lancaster University, England Vilnius Radiocarbon AMS dating laboratory in Vilnius, Lithuania Centre for Isotope Research on Cultural and Environmental heritage (CIRCE) [1], Mathematics and Physics Department [2], Università degli Studi della Campania "Luigi Vanvitelli", Caserta, Italy CEREGE in Aix en Provence, France LMC14 Laboratoire de mesure du carbone 14, at LSCE, Saclay, France LSCE-ECHoMICADAS, at LSCE, Gif-sur-Yvette, France 14Chrono Centre for Climate, the Environment, and Chronology Queen's University Belfast, Northern Ireland Bristol Radiocarbon Accelerator Mass Spectrometer at University of Bristol, England RICH, Royal Institute for Cultural heritage, Brussels, Belgium CologneAMS at University of Cologne, Germany Hertelendi Laboratory of Environmental Studies at ATOMKI, Debrecen, Hungary DREAMS at Dresden, Germany Centre for Isotope Research Rijksuniversiteit Groningen, The Netherlands Beta Analytic Europe in London, England Tandem Laboratory at Uppsala University in Uppsala, Sweden Lund Accelerator Mass Spectrometry Facility at Lund University, Sweden RoAMS Laboratory of the "Horia Hulubei" National Institute for Physics and Nuclear Engineering Măgurele, Romania AMS at the Maier-Leibnitz-Laboratory joint facility of LMU Munich and Technical University of Munich, Germany Oxford Radiocarbon Accelerator Unit, University of Oxford, United Kingdom Poznan Radiocarbon Laboratory, Poland Centre for Dating and Diagnostics (CEDAD), University of Salento, Italy [3] Centro Nacional de Aceleradores, CNA University of Sevilla, Spain NERC Recognised Accelerator Mass Spectrometer at SUERC, Scotland Vienna Environmental Research Accelerator at the University of Vienna, Austria Ion Beam Physics Laboratory of the ETH Zurich and the Paul Scherrer Institute, Switzerland National 1MV AMS Laboratory, TÜBİTAK Marmara Research Center Turkey Nuclear Physics Institute, The Czech Academy of Sciences, Czech Republic
Later in August, Gorbachev resigned as general secretary of the Communist party, and Russian President Boris Yeltsin ordered the seizure of Soviet property. Gorbachev clung to power as the President of the Soviet Union until 25 December 1991, when the USSR dissolved. Fifteen states emerged from the Soviet Union, with by far the largest and most populous one (which also was the founder of the Soviet state with the October Revolution in Petrograd), the Russian Federation, taking full responsibility for all the rights and obligations of the USSR under the Charter of the United Nations, including the financial obligations. As such, Russia assumed the Soviet Union's UN membership and permanent membership on the Security Council, nuclear stockpile and the control over the armed forces. In his 1992 State of the Union Address, US President George H. W. Bush expressed his emotions: "The biggest thing that has happened in the world in my life, in our lives, is this: By the grace of God, America won the Cold War." Bush and Yeltsin met in February 1992, declaring a new era of "friendship and partnership". In January 1993, Bush and Yeltsin agreed to START II, which provided for further nuclear arms reductions on top of the original START treaty.
Sources: en.wikipedia.org
=== Books === In 2003, Pain Killer: An Empire of Deceit and the Origin of America's Opioid Epidemic by the journalist Barry Meier was published. In 2023, Netflix adapted the book into the drama miniseries Painkiller. In 2015, Dreamland: The True Tale of America's Opiate Epidemic by Sam Quinones was released, which connected the growth of the U.S. opioid epidemic to the production and distribution of black-tar heroin from Mexico. In 2018, Dopesick: Dealers, Doctors, and the Drug Company that Addicted America by Beth Macy was released. The book covered the origin and evolution of the opioid epidemic in the United States beginning primarily with the 1996 release of the drug OxyContin, examining on its effects on small town America and the Appalachian region in particular. It received the Los Angeles Times Book Prize for Science and Technology. In 2021, Hulu adapted the book into a drama miniseries, also titled Dopesick, starring Michael Keaton. In 2021, Empire of Pain: The Secret History of the Sackler Dynasty by Patrick Radden Keefe was published, examining the history of the Sackler family, including the founding of Purdue Pharma, its role in the marketing of pharmaceuticals, and the family's central role in the opioid epidemic. The book followed Keefe's 2017 article on the Sackler family in The New Yorker, titled "The Family That Built an Empire of Pain". The book received multiple awards and was longlisted for the 2022 Andrew Carnegie Medal for Excellence in Nonfiction. In 2023, Netflix adapted Keefe's article and Meier's book into the drama miniseries Painkiller.
==== Relapses ==== Relapses are usually unpredictable, occurring without warning. Exacerbations rarely occur more frequently than twice per year. Some relapses, however, are preceded by common triggers and they occur more frequently during spring and summer. Similarly, viral infections such as the common cold, influenza, or gastroenteritis increase their risk.Stress may also raise attack risk modestly, with the strongest evidence for severe stress like war or in PTSD. Many events do not affect rates of relapse requiring hospitalization including vaccination, breast feeding, physical trauma, and Uhthoff's phenomenon.
Modern biochemical research has been greatly aided by the development of new techniques such as chromatography, NMR spectroscopy, electron microscopy and molecular dynamics simulations. These techniques have allowed the discovery and detailed analysis of the many molecules and metabolic pathways in cells.
A highly abundant weed species in Papaver somniferum fields was shown to be Papaver rhoeas. Papaver somniferum and Papaver rhoeas are congeners and belong to the same plant family, which impedes the chemical control of this weed species. Therefore, weed management represents a big challenge and requires technological knowledge from the farmer. In order to increase the efficiency of weed control not only chemical weed control should be applied but also mechanical weed control. For P. somniferum, a growth density of 70 to 80 plants per square metre is recommended. Latex-to-biomass yield is greatest under conditions of slight water deficit.
=== Nigeria === Nigeria is a major oil producer, and its large Dangote refinery has increased production to help meet world shortages. Despite the government and oil companies profiting from this, ordinary citizens are not expected to benefit immediately, due to transport cost increases.
Sources: en.wikipedia.org
It mimics a natural hypothalamic signal that tells the pituitary to release growth hormone. The result is a rise in circulating growth hormone and, indirectly, in insulin-like growth factor 1. Over weeks of treatment this shift is associated with a selective decrease in fat stored inside the abdomen.
The primary measure is usually a cross-sectional abdominal scan that separates internal fat from fat just under the skin. Waist circumference and body weight are recorded as secondary measures because they are easy to obtain but do not distinguish the two fat compartments. Hormone and metabolic blood tests are collected alongside the imaging.
Available follow-up data indicate that visceral fat drifts back toward pretreatment levels once injections stop. The change is therefore best described as treatment-dependent rather than permanent. Investigators continue to debate whether intermittent or repeated courses would preserve any benefit.
The amino acid sequence matches human growth hormone-releasing hormone, but the amino terminus carries a trans-3-hexenoyl group instead of a free amine. That single structural change chiefly affects enzymatic stability rather than receptor selectivity.